Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX), sold 400 shares at $29.13 ($12K) on 2021-12-01, disclosed to the SEC on 2021-12-02.
Scheduled sale ($12k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NRIX | SELL | 2026-08-05 | $100K | — | Filing → |
| NRIX | SELL | 2026-08-05 | $109K | — | Filing → |
| NRIX | SELL | 2026-07-30 | $90K | — | Filing → |